No abstract

is a useful marker to assess systemic oxidative stress. 4 Thus, U-IXP may be a promising novel marker to assess the degree of ROS activity and to predict mortality and morbidity in heart failure patients. 5 Although several biomarkers are clinically available to predict prognosis in heart failure patients, U-IXP has the advantages of being a non-invasive marker and being uniquely associated with the ROS system. In this study we investigated the association between U-IXP and clinical outcomes in heart failure patients. Methods Patient SelectionPatients who were admitted to our institute for the treatment of decompensated heart failure between July 2019 and September 2020 were prospectively included in the present study. Patients aged <20 years, those admitted at the weekend, those who had undergone cardiac intervention within the past 1 month, and those who declined to take part in the study were excluded. All patients provided written informed consent. This study was approved by the Clinical

No abstract

Objective: Some patients with severe aortic stenosis (AS) have cardiac amyloidosis. However, its prevalence and clinical implications, particularly in Japanese patients receiving transcatheter aortic valve replacement (TAVR), remain unknown. Methods: Patients who received 99m Tc-pyrophosphate ( 99m Tc-PYP) scintigraphy tests before TAVR were prospectively included. No patients had any unique symptoms or signs associated with cardiac amyloidosis. Clinical data were compared between those with scintigraphy positive and those without. Results: Among the 102 patients (median age 85 years, 30% men), 5 patients (5%) showed positive deposits in the 99m Tc-PYP scintigraphy tests. There were no statistically significant differences in the baseline and post-TAVR clinical parameters including the severity of AS between the two groups. Following TAVR, plasma B-type natriuretic peptide and cardiac hypertrophy remained unchanged in the scintigraphy-positive group, whereas they improved in the scintigraphy-negative group. Post-TAVR heart failure readmission rate was higher in the scintigraphy-positive group (0.182 versus 0.058 events per year, p = 0.064). Conclusion:The existence of suspected cardiac amyloidosis might be associated with inadequate cardiac unloading and persistent cardiac hypertrophy following TAVR in the Japanese cohort.